http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Simulations Plus Releases ADMET Predictor® (X.3)
-
Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences
-
Simulations Plus Reports Continued Success in Second Phase of AIDD Collaboration with Large Pharmaceutical Company
-
Simulations Plus (SLP) Announces NMPA’s Center for Drug Evaluation Adds Licenses of GastroPlus
-
NMPA’s Center for Drug Evaluation Adds Licenses of GastroPlus®
-
Simulations Plus Reports Third Quarter Fiscal 2021 Financial Results
-
Simulations Plus Celebrates 25 Years in Business
-
Simulations Plus Sets Date for Third Quarter Fiscal Year 2021 Earnings Release and Conference Call
-
Simulations Plus Releases IPFsym version 1A, State-of-the-Art Quantitative Systems Pharmacology (QSP) Software for Idiopathic Pulmonary Fibrosis (IPF)
-
Simulations Plus to Participate in 18th Annual Craig-Hallum Institutional Investor Conference
-
Simulations Plus to Present at 16th Annual Needham Virtual Technology & Media Conference
-
Simulations Plus Uplisted to The Nasdaq Global Select Market®
-
Simulations Plus Releases ADMET Predictor® (X.2)
-
Simulations Plus (SLP) Announces U.S. FDA Renews Licenses of DILIsym Software
-
U.S. FDA Renews Licenses of DILIsym Software
-
Simulations Plus Reports Record Second Quarter Fiscal 2021 Financial Results
-
Simulations Plus Reports Successful Results from AIDD Collaboration with Large Pharmaceutical Company
-
Simulations Plus Sets Date for Second Quarter Fiscal Year 2021 Earnings Release and Conference Call
-
Simulations Plus Forms Scientific Advisory Board for RENAsym Consortium
-
Simulations Plus Hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions
-
Simulations Plus and the University of Pittsburgh Drug Discovery Institute Receive SBIR Grant Funding for Large Molecule Safety Collaboration
-
Simulations Plus to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
-
Simulations Plus Releases GastroPlus® Version 9.8.1
-
Simulations Plus (SLP) Enters Agreement with Distributor in China
-
Simulations Plus Enters Agreement with Distributor in China
-
Simulations Plus Expands Marketing and Sales Operations in South America Through Partnership with the Institute of Pharmaceutical Sciences
-
Simulations Plus Awards Infrastructure Improvement Grant to Makerere University Department of Pharmacology and Therapeutics
-
Simulations Plus to Present at 23rd Annual Needham Virtual Growth Conference
-
Simulations Plus Enters New Funded Collaboration to Improve Lung Exposure Models for Pulmonary Infection Treatments
-
Simulations Plus Reports Record First Quarter FY2021 Financial Results
-
Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides
-
Simulations Plus Sets Date for First Quarter Fiscal Year 2021 Earnings Release and Conference Call
-
Simulations Plus Publishes its Inaugural Environmental, Social and Governance (ESG) Report
-
DILIsym Services Presents Important DILIsym and NAFLDsym Software Applications at the Virtual AASLD Liver Meeting
-
Simulations Plus (SLP) Names Industry Veteran Will Frederick as CFO
-
Simulations Plus Names Industry Veteran Will Frederick as Chief Financial Officer
-
Simulations Plus Reports FY2020 and Fourth Quarter FY2020 Financial Results
-
DILIsym Plays Critical Role in Submission to State of California for Common Analgesic Carcinogenicity Risk Assessment
-
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2020 Earnings Release and Conference Call
-
Simulations Plus to Participate in the Credit Suisse Virtual Healthcare Conference
-
Lixoft Expands MonolixSuite™ in Version 2020R1
-
First Approved Cancer Treatment for TGCT Included DILIsym Simulations in FDA Review
-
Simulations Plus Releases GastroPlus® Version 9.8
-
Simulations Plus Teams Up with the University of Health Sciences and Pharmacy in St. Louis to Secure New Grant Award from the U.S. FDA
-
Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share
-
Simulations Plus (SLP) Extends Partnership with Large Pharmaceutical Company to Further Expand High-Throughput PBPK Capabilities in ADMET Predictor
-
Simulations Plus Extends Partnership with Large Pharmaceutical Company to Further Expand High-Throughput PBPK Capabilities in ADMET Predictor®
-
Simulations Plus Partners with Large Pharmaceutical Company to Validate AI-Driven Drug Design Capabilities in ADMET Predictor®
-
Simulations Plus Releases ADMET Predictor® Version 10.0 (APX)
-
FDA Review of Approved Drug, Ubrogepant, Included DILIsym Simulations

